Clinical Trials/ACTRN12618001552279

ACTRN12618001552279

Completed

Phase 1

Radionuclide therapy using 177Lu-PSMA: a pilot study in men with castrate-resistant prostate cancer (LuPSMA trial)

St Vincent's Hospital0 sites15 target enrollmentSeptember 17, 2018

Conditionscastrate-resistant prostate cancer

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: castrate-resistant prostate cancer
Sponsor: St Vincent's Hospital
Enrollment: 15
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

September 17, 2018

End Date

TBD

Last Updated

7 years ago

Study Type

Interventional

Sex

Male

Investigators

Sponsor

St Vincent's Hospital

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

An early phase clinical trial evaluating the effectiveness of treatment of 177Lu-PSMA with idronoxil in men with castrate-resistant prostate cancer (LuPin Trial)

ACTRN12618001073291St Vincent's Hospital Sydney56

Not yet recruiting

A study to evaluate new treatment for prostate cancer with a type of radiation therapy with radionuclide - Lu psma and to compare with the standard treatment with Abiratetone.Health Condition 1: C61- Malignant neoplasm of prostate

CTRI/2020/10/028341Tata Memorial Hospital

Active, not recruiting

EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPCProstatic NeoplasmsGenital Neoplasms, MaleUrogenital NeoplasmsProstate CancerNeoplasms by SiteNeoplasmsProstatic Disease

NCT05150236Australian and New Zealand Urogenital and Prostate Cancer Trials Group93

177Lu-PSMA RADIOLIGAND THERAPY IN PATIENTS WITH LYMPH NODE METASTATIC HORMONE-SENSITIVE PROSTATE CANCER UNDERGOING ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTIO

NL-OMON52075Vrije Universiteit Medisch Centrum10

Active, not recruiting

177Lu-PSMA RADIOLIGAND THERAPY IN PATIENTS WITH LYMPH NODE METASTATIC HORMONE-SENSITIVE PROSTATE CANCER UNDERGOING ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTIOprostate cancer, eligible for radical prostatectomy and extended pelvic lymph node dissection, with 1-3 pelvic nodal metastases on preoperative PSMA PETTherapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]

EUCTR2020-004991-16-NL10